For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease that had confounded researchers for more than a century. To assess the ...
According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...
MultiCell has granted Eisai a 5-year nonexclusive license to use its Fa2N-4 cells line and MFEâ„¢ culture media at Eisai's Tsukuba Research Laboratories. with the Breaking Science News daily newsletter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback